Loading...
XNAS
URGN
Market cap466mUSD
May 07, Last price  
10.12USD
1D
4.44%
1Q
-7.58%
IPO
-27.71%
Name

Urogen Pharma Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
5.16
EPS
—
Div Yield, %
—
Shrs. gr., 5y
15.87%
Rev. gr., 5y
449.77%
Revenues
90m
+9.29%
00017,530,0008,158,0001,128,00018,00011,799,00048,042,00064,357,00082,713,00090,398,000
Net income
-127m
L+24.09%
-3,306,000-4,557,000-12,689,000-1,941,000-20,000,000-75,657,000-100,530,000-128,484,000-110,820,000-109,163,000-102,244,000-126,874,000
CFO
-97m
L+26.70%
-2,557,000-4,117,000-7,175,0004,189,000-9,571,000-37,334,000-71,017,000-105,886,000-84,892,000-87,559,000-76,376,000-96,766,000
Earnings
May 12, 2025

Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
URL
https://www.urogen.com/
IPO date
May 04, 2017
Employees
193
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
90,398
9.29%
82,713
28.52%
64,357
33.96%
Cost of revenue
66,026
54,975
60,560
Unusual Expense (Income)
NOPBT
24,372
27,738
3,797
NOPBT Margin
26.96%
33.54%
5.90%
Operating Taxes
2,832
3,920
1,135
Tax Rate
11.62%
14.13%
29.89%
NOPAT
21,540
23,818
2,662
Net income
(126,874)
24.09%
(102,244)
-6.34%
(109,163)
-1.50%
Dividends
Dividend yield
Proceeds from repurchase of equity
151,169
67,358
1,351
BB yield
-33.10%
-15.57%
-0.67%
Debt
Debt current
941
Long-term debt
125,040
100,239
100,709
Deferred revenue
Other long-term liabilities
125,178
112,916
98,923
Net debt
(111,645)
(41,231)
1,464
Cash flow
Cash from operating activities
(96,766)
(76,376)
(87,559)
CAPEX
(295)
(194)
(254)
Cash from investing activities
(20,613)
(953)
1,060
Cash from financing activities
194,619
116,931
97,134
FCF
21,117
29,356
1,880
Balance
Cash
236,685
136,968
99,963
Long term investments
4,502
223
Excess cash
232,165
137,334
96,968
Stockholders' equity
(806,051)
(679,247)
(577,148)
Invested Capital
1,045,813
826,346
687,394
ROIC
2.30%
3.15%
0.43%
ROCE
10.17%
18.86%
3.35%
EV
Common stock shares outstanding
42,877
28,834
22,807
Price
10.65
-29.00%
15.00
69.11%
8.87
-6.73%
Market cap
456,637
5.58%
432,515
113.80%
202,296
-4.81%
EV
344,992
391,284
203,760
EBITDA
25,558
29,443
5,614
EV/EBITDA
13.50
13.29
36.30
Interest
12,521
14,715
8,438
Interest/NOPBT
51.37%
53.05%
222.23%